Tranlational Research: A Phase I study of Oxyfedrine and Sulfasalazine in Patients with Solid Tumor

JRCT ID: jRCT1030230529

Registered date:22/12/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: unresectable recurrent solid tumor
• Date of first enrollment: 22/12/2023
• Target sample size: 54
• Study type: Observational

Outcome(s)

• Primary Outcome: Correlation of objective response rate or disease control rate with biomarkers
• Secondary Outcome: Progression-free survival, duration of response, duration of treatment success, correlation of biomarkers with overall survival, etc.

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) Willing to participate in the "XXXX".
2) Written consent has been obtained from the patient for this ancillary study.
3) Age 18 years or older on the date consent is obtained.

• Exclude criteria: 1) Patients who are regarded as inappropriate for enrollment by investigators.

Related Information

• Primary Sponsor: Shitara Kohei
• Source(s) of Monetary Support: Advanced Research and Development Programs for Medical Innovation